Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
recombinant Staphylococcus aureus four-component vaccine
- Development stage
- Preclinical
- Lead developer
- Jiangsu Kunli Biopharmaceutical
- Modality
- Recombinant Proteins and Enzymes, Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
The recombinant Staphylococcus aureus four-component vaccine (E. coli expression system) is a prophylactic protein subunit vaccine developed by Jiangsu Kunli Biopharmaceutical and its subsidiary Shandong Kunli Biopharmaceutical. Expressed using an Escherichia coli system, the vaccine is designed to prevent Staphylococcus aureus infections, including bacteremia, sepsis, and toxic shock syndrome. In July 2025, the Center for Drug Evaluation (CDE) of China's National Medical Products Administration (NMPA) accepted the Investigational New Drug (IND) application (acceptance number CXSL2500611) for this vaccine.
- Other names
- Recombinant Staphylococcus aureus four-component vaccine (E. coli expression system)重组金黄色葡萄球菌四组分疫苗（大肠杆菌）
02
Targets
CP8 (Staphylococcus aureus capsular polysaccharide type 8)MntC (Staphylococcus aureus manganese transport protein C)CP5 (Staphylococcus aureus capsular polysaccharide type 5)ClfA (Clumping factor A)
Beyond the preview
Go deeper on recombinant Staphylococcus aureus four-component vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on recombinant Staphylococcus aureus four-component vaccine.